Elevation of surfactant protein A in plasma and sputum in cigarette smokers

European Respiratory Journal

Volumn 38, Issue 2, 2011, Pages 277-284

  Mazur, W ^a   Toljamo, T ^b   Ohlmeier, S ^c   Vuopala, K ^b   Nieminen, P ^c   Kobayashi, H ^d   Kinnula, V L ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b LAPLAND CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Biomarker; Chronic obstructive pulmonary disease; Induced sputum; Screening; Smoking; Surfactant protein A

Indexed keywords

SURFACTANT PROTEIN A;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; COUGHING; ENZYME IMMUNOASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG DISEASE; LUNG FUNCTION; LYMPHOCYTE; MACROPHAGE; MALE; MAXIMAL EXPIRATORY FLOW; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING CESSATION; SPUTUM ANALYSIS; SUPERNATANT; SYMPTOMATOLOGY;

AGE FACTORS; AGED; COUGH; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MIDDLE AGED; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; RESPIRATORY FUNCTION TESTS; SMOKING; SMOKING CESSATION; SPUTUM;

EID: 80051518662     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00110510     Document Type: Article

References (49)

1. Greene KE, King TE Jr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19: 439-446. (Pubitemid 34256957)
2. Ishii H, Mukae H, Kadota J, et al. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax 2003; 58: 52-57. (Pubitemid 36135359)
3. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135: 1557-1563.
4. Phelps DS, Umstead TM, Mejia M, et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest 2004; 125: 617-625. (Pubitemid 38223644)
5. Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 162: 258-263. (Pubitemid 30469830)
6. Wattiez R, Hermans C, Cruyt C, et al. Human bronchoalveolar lavage fluid protein two-dimensional database: study of interstitial lung diseases. Electrophoresis 2000; 21: 2703-2712.
7. Behera D, Balamugesh T, Venkateswarlu D, et al. Serum surfactant protein-A levels in chronic bronchitis and its relation to smoking. Indian J Chest Dis Allied Sci 2005; 47: 13-17.
8. Kida K, Oda H, Yamano Y, et al. Effects of cigarette smoking on the serum concentration of lung surfactant protein A (SP-A). Eur Respir J 1997; 10: 2124-2126. (Pubitemid 27406454)
9. Kobayashi H, Kanoh S, Motoyoshi K. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers 2008; 13: 385-392. (Pubitemid 351865814)
10. Nomori H, Horio H, Fuyuno G, et al. Serum surfactant protein A levels in healthy individuals are increased in smokers. Lung 1998; 176: 355-361. (Pubitemid 28559319)
11. Robin M, Dong P, Hermans C, et al. Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur Respir J 2002; 20: 1152-1161. (Pubitemid 35331872)
12. Kishore U, Bernal AL, Kamran MF, et al. Surfactant proteins SP-A and SP-D in human health and disease. Arch Immunol Ther Exp (Warsz) 2005; 53: 399-417. (Pubitemid 43116640)
13. Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol 2008; 122: 861-879.
14. Mason RJ, Greene K, Voelker DR. Surfactant protein A and surfactant protein D in health and disease. Am J Physiol 1998; 275: L1-L13.
15. Pastva AM, Walker JK, Maddox LA, et al. Nitric oxide mediates a relative airway hyporesponsiveness to lipopolysaccharide in surfactant protein-A deficient mice. Am J Respir Cell Mol Biol 2011; 44: 175-184.
16. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc 2007; 4: 252-257. (Pubitemid 47036444)
17. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005; 5: 58-68. (Pubitemid 40070331)
18. Chuang CY, Chen TL, Chen RM. Molecular mechanisms of lipopolysaccharide- caused induction of surfactant protein-A gene expression in human alveolar epithelial A549 cells. Toxicol Lett 2009; 15, 19: 132-139.
19. Hu Q, Zhang H, Xiong S, et al. The alteration and significance of surfactant protein A in rats chronically exposed to cigarette smoke. J Huazhong Univ Sci Technolog Med Sci 2008; 28: 128-131.
20. Seppanen O, Glumoff V, Paananen R, et al. Transcription factors NF-kB and C/EBPd and IL-1-induced expression of surfactant protein A in lung explants during the perinatal period. Biol Neonate 2005; 87: 152-159. (Pubitemid 40591437)
21. Shibata Y, Abe S, Inoue S, et al. Altered expression of antimicrobial molecules in cigarette smoke-exposed emphysematous mice lungs. Respirology 2008; 13: 1061-1065.
22. Subramaniam S, Whitsett JA, Hull W, et al. Alteration of pulmonary surfactant proteins in rats chronically exposed to cigarette smoke. Toxicol Appl Pharmacol 1996; 140: 274-280. (Pubitemid 26366850)
23. Beeh KM, Beier J, Kornmann O, et al. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003; 123: 778-783. (Pubitemid 36315493)
24. Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med 2001; 95: 999-1002. (Pubitemid 34013550)
25. Purokivi M, Randell J, Hirvonen MR, et al. Reproducibility of measurements of exhaled NO, and cell count and cytokine concentrations in induced sputum. Eur Respir J 2000; 16: 242-246. (Pubitemid 30624942)
26. Ohlmeier S, Vuolanto M, Toljamo T, et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res 2008; 7: 5125-5132.
27. Toljamo T, Kaukonen M, Nieminen P, et al. Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care 2010; 28: 41-46.
28. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
29. Dunn C, Deroo L, Rivara FP. The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. Addiction 2001; 96: 1725-1742. (Pubitemid 34014247)
30. Global Strategy for Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease, 2010. Available from: www.goldcopd.com.
31. Viljanen AA, Halttunen PK, Kreus KE, et al. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest Suppl 1982; 159: 5-20. (Pubitemid 12127706)
32. Djukanovic R, Sterk PJ, Fahy JV, et al. Standardised methodology of sputum induction and processing. Eur Respir J 2002; 20: Suppl. 37, 1s-2s. (Pubitemid 35024260)
33. Kelly MM, Keatings V, Leigh R, et al. Analysis of fluid-phase mediators. Eur Respir J 2002; 20: Suppl. 37, 24s-39s. (Pubitemid 35024264)
34. Rytila P, Rehn T, Ilumets H, et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006; 7: 69.
35. Madsen J, Tornoe I, Nielsen O, et al. Expression and localization of lung surfactant protein A in human tissues. Am J Respir Cell Mol Biol 2003; 29: 591-597. (Pubitemid 37357710)
36. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000; 162: 1109-1114.
37. Mutti A, Corradi M, Goldoni M, et al. Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma. Chest 2006; 129: 1288-1297.
38. Sorensen GL, Husby S, Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology 2007; 212: 381-416. (Pubitemid 46825244)
39. Honda Y, Takahashi H, Kuroki Y, et al. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996; 109: 1006-1009. (Pubitemid 26113645)
40. Vlachaki EM, Koutsopoulos AV, Tzanakis N, et al. Altered surfactant protein-A (SP-A) expression in type II pneumocytes in COPD. Chest 2010; 137: 37-45.
41. Mason GR, Peters AM, Bagdades E, et al. Evaluation of pulmonary alveolar epithelial integrity by the detection of restriction to diffusion of hydrophilic solutes of different molecular sizes. Clin Sci (Lond) 2001; 100: 231-236. (Pubitemid 32215992)
42. Mason GR, Uszler JM, Effros RM, et al. Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking. Chest 1983; 83: 6-11. (Pubitemid 13172742)
43. Morrison D, Rahman I, Lannan S, et al. Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers. Am J Respir Crit Care Med 1999; 159: 473-479. (Pubitemid 29084868)
44. Betsuyaku T, Kuroki Y, Nagai K, et al. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J 2004; 24: 964-970. (Pubitemid 39642287)
45. Shijubo N, Honda Y, Itoh Y, et al. BAL surfactant protein A and Clara cell 10-kDa protein levels in healthy subjects. Lung 1998; 176: 257-265. (Pubitemid 28252562)
46. Woodworth BA, Lathers D, Neal JG, et al. Immunolocalization of surfactant protein A and D in sinonasal mucosa. Am J Rhinol 2006; 20: 461-465. (Pubitemid 44390227)
47. Paananen R, Sormunen R, Glumoff V, et al. Surfactant proteinsAand D in Eustachian tube epithelium. Am J Physiol 2001; 281: L660-L667.
48. Oberley RE, George CL, Snyder JM. A new tool to investigate differences between human SP-A1 and SP-A2. Am J Physiol 2007; 292: L1050-L1051. (Pubitemid 47084849)
49. Laitinen T, Hodgson U, Kupiainen H, et al. Real-world clinical data identifies gender-related profiles in chronic obstructive pulmonary disease. COPD 2009; 6: 256-262.